Assessment of the Long-term Safety and Efficacy of Erenumab During Open-label Treatment in Patients With Chronic Migraine

Stewart J. Tepper,1 Messoud Ashina,2 Uwe Reuter,3 Jan L. Brandes,4 David Doležil,5 Stephen Silberstein,6 Paul Winner,7 Feng Zhang,8 Sunfa Cheng,9 Daniel D. Mikol9

Contact Us

Do you have a question about this clinical trial? Request a visit from your Medical Science Liaison.

1Geisel School of Medicine at Dartmouth, Hanover, NH, USA; 2Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark; 3Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany; 4Nashville Neuroscience Group and Vanderbilt University Department of Neurology, Nashville, TN, USA; 5Dado Medical sro, Prague Headache Center, Prague, Czech Republic; 6Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA; 7Premiere Research Institute, Nova Southeastern University, West Palm Beach, FL, USA; 8Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA; 9Global Development, Amgen Inc., Thousand Oaks, CA, USA.